- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01762969
Treatment Modification Based on Early Assessment of CML Patients
Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
To establish a national protocol for the treatment of patients with CML. Patients will be stratified by molecular response, and treatment will be adjusted accordingly.
Secondary outcomes To compare clinical outcomes of patients at high risk (transcript level above 10%) to those at low risk (<10%) while using the early switch approach To evaluate the prognostic value of EUTOS, HASFORD, and SOKAL scores using the early switch strategy Patients Patients may be enrolled to the protocol prior to any TKI treatment or at any time point from commencement of imatinib (started at 400 mg daily) and prior to 3 months assessment, if all the necessary baseline data is available, and all other inclusion criteria are met (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib)
Inclusion criteria:
Adult patients within 6 months after the diagnosis of Philadelphia chromosome-positive CML in the chronic phase
- who were not previously treated (with the exception of hydroyurea) for CML or
- who were treated with imatinib for CML for up to 3 months, and prior to 3 months assessment (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib).
- Age > 18 years Diagnosis of CML will be made by conventional cytogenetic (chromosome banding analysis) and/or interphase fluorescent in situ hybridization (FISH) analysis of bone marrow containing at least one Philadelphia chromosome-positive metaphase cell. If BCR-ABL1 fusion gene (Philadelphia chromosome) is not detected by conventional cytogenetic analysis, the diagnosis of CML can be confirmed based on FISH analysis or molecular analysis (demonstration of bcr-abl by polymerase chain reaction (PCR)).
Inclusion of patients with any organ dysfunction (cardiac, renal, respiratory, liver) can be done based on the decision of the treating physician.
Exclusion criteria:
Patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib (i.e., nilotinib, dasatinib) before study entry. Patients may take hydroxyurea or anagrelide for up to 4 weeks prior to imatinib treatment.
Interventions Imatinib 400 mg once daily Response will be assessed after 3 months of therapy. A complete blood count to assess hematologic response and a bone marrow biopsy and/or aspirate, including cytogenetic analysis and molecular analysis for quantitative RT-PCR for BCR-ABL1/ABL will be performed.
Response assessment Assessment of response by molecular analysis of bcr-abl1 will be performed in certified and standardized laboratories (a list of certified laboratories will be distributed).
If a patients has achieved CHR and BCR-ABL1/ABL ISI <10% at 3 months then imatinib will be continued at the dose of 400 mg daily.
If a patient has achieved CHR and BCR-ABL1/ABL ISI >10% at 3 months then imatinib will be stopped and nilotinib 300 mg twice daily or dasatinib 100 mg once daily will be instituted. ECG will be done prior to any change of therapy.
Mutation analysis is recommended prior to the commencement of nilotinib or dasatinib.
Patients will continue to receive the study treatment until the disease will progress or unacceptable toxic effects will developed. In the event of disease progression or the occurrence of adverse event treatment can be stopped or changed under the discretion of the treating physician.
Outcomes Rate of CCyR at 12 months CCyR is defined as absence of Ph-positive metaphases, determined on the basis of G-banding in at least 20 cells in metaphase per bone marrow sample Overall survival Rate of major molecular response at 6, 12, 18, 24 months Cumulative rate of optimal response at 12, 18 months
PFS:
Time from commencement of imatinib till meeting ELN criteria for failure, progression to AP/BC, or death from any cause
EFS:
Time from commencement of imatinib till meeting ELN criteria for failure, progression to AP/BC, grade 3 to 4 adverse event, drug discontinuation (except of the change of imatinib at 3 months according to molecular response), or death from any cause
Safety:
Adverse events will be classified according to the CTCAE NCI US v.3.0 Severe AE
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Liat vidal, MD MSc
- Email: vidallit@yahoo.com
Study Contact Backup
- Name: Ofer Shpilberg, MD MPH
- Phone Number: +972-3-9377906
Study Locations
-
-
-
Petah tikva, Israel, 49100
- Recruiting
- Rabin Medical Center
-
Contact:
- Liat vid
- Email: vidallit@yahoo.com
-
Contact:
- Ofer, Shpilberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Adult patients within 6 months after the diagnosis of Philadelphia chromosome-positive CML in the chronic phase
- who were not previously treated (with the exception of hydroyurea) for CML or
who were treated with imatinib for CML for up to 3 months, and prior to 3 months assessment (patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib).
2. Age > 18 years Diagnosis of CML will be made by conventional cytogenetic (chromosome banding analysis) and/or interphase fluorescent in situ hybridization (FISH) analysis of bone marrow containing at least one Philadelphia chromosome-positive metaphase cell. If BCR-ABL1 fusion gene (Philadelphia chromosome) is not detected by conventional cytogenetic analysis, the diagnosis of CML can be confirmed based on FISH analysis or molecular analysis (demonstration of bcr-abl by polymerase chain reaction (PCR)).
Inclusion of patients with any organ dysfunction (cardiac, renal, respiratory, liver) can be done based on the decision of the treating physician.
Exclusion Criteria:
Patients will be excluded if they received treatment with a tyrosine kinase inhibitor other than imatinib (i.e., nilotinib, dasatinib) before study entry. Patients may take hydroxyurea or anagrelide for up to 4 weeks prior to imatinib treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Modified by molecular response
Patients will be treated with imatinib upon diagnosis of CML.
Molecular response will be assessed at 3 months of therapy.
Based on molecular response imatinib will be continued or changed to another TKI
|
Patients will be treated with imatinib upon diagnosis of CML.
Molecular response will be assessed at 3 months of therapy.
Based on molecular response imatinib will be continued or changed to another TKI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of complete cytogenetic response
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 12 months
|
12 months
|
|
Rate of major molecular response
Time Frame: 12, 24 months
|
Cumulative rate of optimal response at 12, 18 months
|
12, 24 months
|
PFS
Time Frame: 12 months
|
Time from commencement of imatinib till meeting ELN criteria for failure, progression to AP/BC, or death from any cause
|
12 months
|
Severe Adverse events
Time Frame: 12 months
|
Adverse events will be classified according to the CTCAE NCI US v.3.0
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CML-IS001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CML
-
Inhibikase Therapeutics, Inc.Recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Novartis PharmaceuticalsActive, not recruitingGIST and CMLChina, Turkey, Singapore, France, Switzerland, Thailand, United States, Romania, Hong Kong, Finland, United Kingdom
-
Novartis PharmaceuticalsCompletedImatinib | CMLKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
Novartis PharmaceuticalsCompleted
-
National Taiwan University HospitalCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous LeukemiaUnited States
-
Sheffield Children's NHS Foundation TrustWithdrawnGene Expression Profiles in CML Non-respondersUnited Kingdom
Clinical Trials on Treatment modification based on molecular response at 3 months
-
Nordsjaellands HospitalActive, not recruitingInflammatory Bowel Diseases
-
Memorial Sloan Kettering Cancer CenterWang Initiative in Lung Cancer Clinical TrialsWithdrawnNon Small Cell Lung CancerUnited States
-
Sofia Perea, Director Clinical Trials Unit.UnknownCarcinoma, Pancreatic DuctalSpain
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)Completed
-
Lia BallyUniversity of PadovaRecruitingPost-bariatric Hypoglycaemia | Roux-en-Y Gastric BypassSwitzerland
-
Scottsdale HealthcareTranslational Genomics Research InstituteCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingCancer | Immune Checkpoint Inhibitors | Metabolism DisorderFrance
-
Centre Francois BaclesseUniversity Hospital, CaenTerminatedRelation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell CarcinomaRenal Cell CarcinomaFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Centre Hospitalier Universitaire, AmiensCompletedHepatocellular Carcinoma | Perfusion ScannerFrance